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Abstract Obesity, diabetes and consequently atheroscle-
rotic vascular disease have become major health and public
health issues worldwide. The increasing and staggering
prevalence of obesity might not only be explained by
nutritional habits or the reduction of energy expenditure
through decreased physical activity. In addition, recent
studies have focused on intestinal microbiota as environ-
mental factors that increase energy yield from diet, regulate
peripheral metabolism and thereby increase body weight.
Obesity is associated with substantial changes in composi-
tion and metabolic function of gut microbiota, but the
pathophysiological processes driving this bidirectional
relationship have not been fully elucidated. This review
discusses the relationships between the following: compo-
sition of gut microbiota, energy extracted from diet,
synthesis of gut hormones involved in energy homeostasis,
production of butyrate and the regulation of fat storage.
Keywords Gutmicrobiota.Insulinresistance.Obesity.
Review.Type2diabetes
Abbreviations
FIAF Fasting-induced adipose factor
FISH Fluorescent in situ hybridisation
GBP Gastric bypass surgery
GIP Gastric inhibitory peptide
GLP-1 Glucagon like peptide-1
GPR41 G protein-coupled receptor 4
LPL Lipoprotein lipase
LPS Lipopolysaccharide
PYY Peptide YY
SCFA Short-chain fatty acids
Introduction
The twin epidemics of obesity and type 2 diabetes mellitus
have generated a wealth of literature regarding the intricate
mechanisms of human metabolism in general and insulin
resistance in particular. To date, many of the mechanistic
studies have mainly focused on the biology of relationships
between various human organs and cell systems. In
contrast, geneticists have mainly focused on the human
genome in their attempts to unravel the risk factors for type
2 diabetes mellitus. Nevertheless, there is an increasing
body of literature that directs its attention to a possible third
culprit: the gut microbiota [1–3]. These micro-organisms
and thus their bacterial genome (also called the micro-
biome) are increasingly considered important pathogenic
factors in various diseases ranging from gastrointestinal
tract diseases such as inflammatory bowel disease to
obesity [4]. With hindsight, this should hardly have come
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nature. The purpose of this review is to elaborate on how
gut microbiota might contribute to the pathophysiology of
obesity and type 2 diabetes mellitus.
Obesity is an increasingly common condition associated
with an increased risk of type 2 diabetes mellitus and
cardiovascular disease [5]. The causal role of obesity in
type 2 diabetes is highlighted by the fact that preventive
weight reduction is associated with a decreased incidence
of diabetes mellitus in multiple studies [6, 7]. Moreover,
weight loss following bariatric surgery in morbidly obese
patients with type 2 diabetes leads to a rapid reversal of the
pathophysiology and subsequent resolution of diabetes
mellitus [7]. Interestingly, this glycaemic improvement
actually occurs before weight loss. In addition, there is
growing evidence that the increasing prevalence of obesity
might not only be explained by nutritional habits or the
reduction of energy expenditure through decreased physical
activity. Thus even within families, some individuals seem
more susceptible to diet-induced weight gain and hyper-
glycaemia, suggesting that other factors than those residing
in the human genome are involved [8–10]. The gut
microbiota could therefore be prime candidates to explain
part of the residual differences in body weight between
individuals.
The human gut microbiota
Until recently, our understanding of human gut microbiota
was limited by technical issues. Although a large fraction of
the dominant (anaerobic) gut microbiota still remains
impossible to culture, the development of 16S ribosomal
RNA gene-based approaches has facilitated the identifica-
tion and classification of bacteria.
The human intestinal tract contains a large variety of
micro-organisms, of which bacteria are the most dominant
and diverse (Fig. 1). As a whole, the microbiome is more
than 100 times larger than the human genome [11]. Thus,
intestinal microbiota can be viewed as an ‘exteriorised
organ’ that contributes to overall metabolism and plays a
role in converting food into nutrients and energy. The
community of at least 10
14 bacteria is dominated by
anaerobic bacteria and composed of 500 to 1000 different
species [12]. Three bacterial divisions, the Firmicutes
(gram-positive), Bacteroidetes (gram-negative) and Actino-
bacteria (gram-positive) dominate the adult human gut
microbiota. The Firmicutes is the largest bacterial phylum
and contains more than 200 genera, including Lactobacil-
lus, Mycoplasma, Bacillus and Clostridium. The Bacter-
oidetes (including about 20 genera) and the Actinobacteria
(gram-positive) also belong to the dominant gut microbiota,
but the latter are frequently missed by RNA gene
sequencing and can only be detected by fluorescent in situ
hybridisation (FISH) [13].
Fetuses are sterile in uteri, but in the first year of life the
infant intestinal tract progresses from sterility to extremely
dense colonisation with a mixture of microbes broadly
similar to that found in the adult intestine [12]. During birth
and rapidly thereafter, bacteria from the mother and the
surrounding environment colonise the infant’s gut. After
this inoculation, the microbiota changes rapidly, presum-
Fig. 1 Phylogenetic tree repre-
senting the groups of bacteria
most frequently detected in
human faeces using 16S rRNA
gene sequencing. The extent of
the bold areas indicate diversity
and abundance of the bacterial
groups
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the gut microbiota in host individuals has fully matured.
The final composition of the microbiota is influenced by the
host genotype, colonisation history, the physiology of the
host and an array of environmental factors [14]. Genetic
makeup of the individual also influences the composition of
the core microbiota, as was shown in several studies [10,
14]. For instance, the microbiota of monozygotic twins
living separately, is notably more similar than the micro-
biota of unrelated individuals [10]. In contrast, the
environment seems to be of less importance, since marital
partners did not have a significantly greater similarity of
bacterial communities than unrelated individuals, despite
the fact that these partners lived in the same environment
and had similar dietary habits [14].
The effect of diet on the composition of the infant
microbiota is not clear; numerous studies report a lower
abundance of bifidobacteria in the microbiota of formula-
fed infants relative to breast-fed infants [15, 16], yet other
reports have found no such differences [17]. The transfor-
mation to adult-type microbiota is probably triggered by
multiple host and external factors [18]. After the transfor-
mation to adult-type microbiota, the gut microbiota remains
remarkably constant until the 7th decade, fluctuating around
an individual core of stable colonisers [13, 19, 20]. During
life, the composition of these micro-organisms can be modu-
lated by antibiotics. Short-term treatment in humans with a
single dose of oral antibiotics affects the gut microbiota for
as long as 4 weeks before it then tends to revert to its
original composition [21]. In conclusion, each individual has
his or her own personal and unique microbiota, with a large
variability in microbiota between individuals. This impres-
sive diversity complicates the studies that attempt to
establish relationships between the host’s health and the
presence of specific microbial populations [13, 19].
Gut microbiota and metabolism
A number of studies have revealed that specific relation-
ships exist between intestinal microbiota and human
metabolism (Fig. 2). Gordon and his colleagues pioneered
the investigation of gut microbiota as an environmental
factor influencing fat storage and obesity. They found that
young conventionally reared mice have 42% more total
body fat and 47% more gonadal fat than germ-free mice [22].
Fig. 2 Possible links between the gut microbiota and metabolism. Details, see main text. Continuous lines, likely pathway; dotted lines, putative
pathway
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energy intake than germ-free mice. The presence of micro-
biota in itself apparently increased the energy yield from the
host organism’s diet. Following up on this observation, the
authors demonstrated that colonisation of young germ-free
mice with microbiota from conventionally reared mice
produces a 60% increase in body fat mass that is associated
with increased insulin resistance, despite lower energy
intake. These same researchers also demonstrated that faeces
transplantation with microbiota from obese mice (ob/ob)
results in a significantly greater increase in total body fat
than colonisation with microbiota from lean donors [23].
Again, these findings underscore, in obese individuals, the
increased efficiency of microbiota in extracting energy from
diet [22, 24].
Studies of germ-free and control mice have also revealed
that microbiota direct the host to increased hepatic
triacylglycerol and glucose production. In fact, microbial
colonisation of the gut might suppress expression of the
fasting-induced adipose factor (FIAF), leading to suppres-
sion of this lipoprotein lipase (LPL) inhibitor and hence to
increased activity of LPL. Increased LPL activity promotes
increased uptake of fatty acids and triacylglycerol accumu-
lation in adipocytes. The physiological importance of FIAF
was further established by studying germ-free Fiaf (also
known as Angptl4)-knockout and wild-type mice. In
contrast to the situation in wild-type mice, germ-free Fiaf-
knockout mice are similarly obese to their conventionally
reared counterparts, indicating that FIAF is a key modulator
of the microbiota-induced increase in fat storage [22].
Furthermore, Backhed and colleagues have also demon-
strated that germ-free mice have increased levels of
phosphorylated AMP-activated protein kinase in muscle
and liver, which would stimulate NEFA oxidation [25].
Therefore, germ-free animals seem protected from diet-
induced obesity by two complementary, but independent
mechanisms, which result in decreased fatty acid storage:
(1) elevated levels of FIAF; and (2) increased AMP-
activated protein kinase activity.
Another pathway affecting host energy storage is the
bacterial fermentation of complex dietary carbohydrates to
monosaccharides and short-chain fatty acids (SCFA). These
SCFAs bind to G protein-coupled receptor 4 (GPR41),
which is produced by enteroendocrine cells in the intestine.
Activation of GPR41 enhances production of peptide YY
(PYY), an enteroendocrine cell hormone that normally
inhibits gut motility, increases intestinal transit rate and
reduces extraction of energy (SCFAs) from the diet, thus
affecting peripheral glucose utilisation [26].
In summary, a large body of evidence generated in
animal models has revealed a relationship between gut
microbiota composition and obesity; however, this hypoth-
esis remains to be tested in the human setting.
Altered gut microbiota in obesity
It is now increasingly accepted that the composition of
intestinal microorganisms may change with body weight.
Ley et al. [27] recently analysed 5,088 bacterial 16S rRNA
gene sequences from fat ob/ob mice, lean ob/+ mice and
wild-type siblings. They demonstrated that obese animals
have a 50% reduction in the abundance of Bacteroidetes
and a proportional increase in Firmicutes. Ob/ob mice also
harboured more methanogenic Archaea, which may in-
crease the efficiency of bacterial fermentation [23]. Meta-
genomic analyses revealed that the caecal microbiota in the
ob/ob mice were producing more SCFA through increased
fermentation of dietary polysaccharides. The increased
extraction of energy from dietary fibres may partly
contribute to the excessive weight gain of ob/ob mice
[23]. In this study, changes in Bacteroidetes and Firmicutes
were noted across the division, i.e. they were not due to
blooms or extinction of specific organisms. However, upon
induction of obesity in mice, the increase in Firmicutes
seemed mainly attributable to an increase in the Mollicutes
class [28]. Similar to these animal experiments, Bacteroi-
detes tend to decrease and Firmicutes to increase in the
faeces of obese compared with lean humans [19] (see also
Fig. 2). Obese people harbour fewer Bacteroidetes and more
Firmicutes than lean controls, whereas upon a carbohydrate-
or fat-restricted low-energy diet, Bacteroidetes increased and
Firmicutes decreased. These data suggest a relationship
between obesity and the diversity of intestinal microbiota.
Interestingly, the increase in Bacteroidetes was significantly
correlated with weight loss achieved, but not with total
energy intake, suggesting interactions between diet, gut
microbiota and host metabolism [19, 29].
However, other human studies do not support these
specific changes. Duncan et al. [3], using FISH to monitor
faecal bacteria, could not confirm this ‘high Firmicutes/low
Bacteroidetes’ hypothesis. In fact, they reported no differ-
ences in the proportion of Bacteroidetes measured in faecal
samples between obese and non-obese participants. They
also found no significant relationship between BMI and the
proportion of Bacteroidetes. They did, however, confirm a
significant diet-dependent reduction in Firmicutes in faecal
samples from obese individuals on a low-carbohydrate diet.
In accordance with this last study, Zhang et al. [30] found
in a sequencing-based study that there was no difference
between the fractions of Bacteroidetes in obese and non-
obese participants. These authors showed that gastric
bypass surgery (GBP) strongly altered gut microbiota and
resulted in a large increase in Gammaproteobacteria
(members of the family Enterobacteriaceae), a proportional
decrease in Firmicutes and a loss of methanogens.
In line with this, a recent study by Schwiertz et al. [31]
linked obesity as well as the composition of human
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authors were unable to identify any correlation between
obesity and higher proportions of Firmicutes; they also
suggested that not the ratio of Firmicutes: Bacteroidetes is
important, but rather the amount of SFCA produced.
Finally, Kalliomaki et al. [32] examined whether early
differences in faecal microbiota composition in children
predict subsequent obesity. The bifidobacterial numbers in
faecal samples during infancy, as assessed by FISH with
additional flow cytometry, were lower in children with
subsequent obesity, suggesting that variations in gut micro-
biota early in life may confer an increased risk of
developing obesity in later life. Thus, the relationships
between the various bacterial groups and obesity still
remain a matter of debate.
Gut microbiota and inflammation
Obesity and diabetes are both characterised by low-grade
inflammation of unclear origin. In in vitro and animal
models an increase in proinflammatory cytokines, such as
TNF-α, has led to tissue insulin resistance [33]. Cani et al.
demonstrated that bacterial lipopolysaccharide (LPS) is a
gut microbiota-related factor that triggers secretion of
proinflammatory cytokines [34]. LPS is continuously
produced in the gut through lysis of gram-negative bacteria.
In fact, in the study mentioned above, continuous subcuta-
neous low-rate infusion of LPS led to excessive weight gain
and insulin resistance in mice. Moreover, LPS receptor
Cd14-knockout mice tend to be resistant to this chronic
inflammatory state. Cani et al. [35] showed that a high-fat
diet decreases the number of bifidobacteria and increases
plasma LPS. They also demonstrated that modulation of gut
microbiota, e.g. by antibiotic treatment or dietary interven-
tion with oligofructoses, reduced glucose intolerance,
decreased body weight gain and inhibited inflammation in
mice [36, 37]. These findings suggest that changes in the
gut microbiota could be responsible for increased endotox-
aemia in response to a high-fat diet, which in turn would
trigger the development of obesity and diabetes mellitus.
Another putative pathway linking microbiota to chronic
inflammation could be butyrate bioavailability as obese
participants are characterised by decreased plasma butyrate
levels [38]. Apart from its well-known function as an
essential energy source for colon epithelial cells, butyrate
also has anti-inflammatory properties [39–41]. The two
major butyrate-producing bacterial groups are the Rose-
buria/E. rectale species and F. prausnitzii (cluster of
Firmicutes). Many studies show that the dietary intake of
fermentable carbohydrates can influence butyrate produc-
tion [42, 43]. Particularly, diets containing high levels of
non-digestible carbohydrates stimulate the growth of
particular butyrate-producing bacteria and therefore lead
to elevated plasma levels of butyrate. Interestingly, older
publications showed that increasing plasma levels of
butyrate improve insulin sensitivity and increase energy
expenditure in animal models of diet-induced obesity
[44, 45]. Thus, the available evidence suggests that
butyrate production from food glycans could be a contrib-
uting factor to obesity. Although the exact pathophysiolog-
ical processes driving this bidirectional relationship are not
yet elucidated [46], the potential involvement of this SCFA
may open up interesting therapeutic avenues in the fight
against obesity.
Gut microbiota and gut hormones
The gut communicates with areas in the hypothalamus that
control energy balance by means of neural and endocrine
pathways. Gut hormones are produced by specialised
enteroendocrine cells scattered along the gastrointestinal
tract from the stomach to the distal colon. Although these
account for only 1% of the cells in the intestinal mucosa,
the gastrointestinal tract can be regarded as a major
endocrine organ.
Incretins are gut hormones that potentiate glucose-
induced insulin secretion and may be responsible for up
to 70% of postprandial insulin secretion [47]. The two main
incretins are gastric inhibitory peptide (GIP) and glucagon
like peptide-1 (GLP-1). GIP is secreted by K-cells and
released from the upper small intestine (duodenum and
proximal jejunum) in response to oral ingestion of
carbohydrates and lipids. GLP-1 is mainly produced in
mucosal L cells, located in the distal intestine (ileum and
colon), but also in pancreatic alpha cells as well as in
neurons from several brain areas. The secretion of GIP in
type 2 diabetes is normal, whereas that of GLP-1 is reduced
[47, 48]. GLP-1 secretion also seems to be reduced and
delayed in obese patients compared with lean, healthy
controls [49]. Therefore, different intestinal microbiota
composition in obese humans may possibly contribute to
this reduced GLP-1 secretion.
The secretion pattern of GLP-1 is biphasic, with an
initial rapid rise that occurs 15 to 30 min after ingestion of a
meal [50]. This quick rise occurs before nutrients can reach
the ileum, where the GLP-1-producing L cells are located.
These observations make it unlikely that GLP-1 release is
only stimulated by direct action of nutrients on L cells. In
line with the idea of a neuroendocrine loop, several
peptides and neurotransmitters have been suggested to
trigger GLP-1 secretion [51]. For example, GIP released
when nutrients are present in the upper intestine was shown
to be a potent stimulus of the first peak in GLP-1 secretion
[51]. GLP-1 release is also believed to be triggered by the
610 Diabetologia (2010) 53:606–613autonomic nervous system [51].The second peak of GLP-1
secretion is believed to occur as a result of direct
interactions between nutrients and L cells, which also
stimulate GLP-1 secretion. In this regard, different nutrient
compositions of a meal result in different peptide release as
glucose and fat have been found to be potent stimulators of
GLP-1 secretion, whereas proteins do not appear to
stimulate GLP-1 release [52]. Experiments with alpha-
glucosidase inhibitors such as acarbose, which delays
digestion and absorption of carbohydrates and causes a
transfer of nutrients to distal segments of the intestine,
support this action. Thus treatment with acarbose reduces
GIP secretion, but augments GLP-1 secretion and improves
glucose tolerance in diabetic participants [53].
The modulation of gut peptides involved in the control
of glucose homeostasis could be one mechanism by which
the modulation of gut microbiota via specific dietary
fibres is associated with an improvement of metabolic
disorders. For example, feeding rats with the prebiotic
fibre oligofructose led to an increase in jejunal GIP
concentrations and caecal GLP-1 [54]. Interestingly,
oligofructose feeding in rats promotes L-cell differentiation
in the proximal colon, contributing to higher endogenous
GLP-1 production and subsequent improvement of diabetes
induced by high-fat diet in mice [55]. Several studies have
shown that prebiotics containing short-chain oligosacchar-
ides decrease food intake, fat mass development and
hepatic steatosis in normal and obese rats. In humans, the
addition of non-digestible carbohydrates (oligofructose) to
the diet also protects against body weight gain, fat mass
development and serum triacylglycerol accumulation in-
duced by a high-fat diet [56, 57]. Furthermore, oligofruc-
tose has been shown to promote satiety in healthy humans
[57].
Similarly, GBP results in improvement of glycaemic
control [58–60]. This effects seems to occur rapidly after
surgery and often prior to substantial weight loss. The rapid
effect of GBP on weight loss and metabolic improvement
could be partly due to changes in gut hormone levels after
surgery. Several studies have reported an increase in
postprandial plasma levels of PYY and/or GLP-1 as early
as 2 days after bypass [61]. The mechanism by which GBP
causes increased gut hormone production still remains
unclear, but it is obvious that the altered anatomy after
GBP is the main raison for changes in gut hormone release.
For example after GBP, nutrients reach the distal small
intestine more rapidly, enhancing the release of GLP-1,
which improves glucose metabolism. Altered microbial
composition after GBP may also contribute to the increased
release of gut hormones. Secretion of PYY, another
hormone produced in the distal gut, was also found to be
increased after GBP. This exaggerated beneficial response
observed after GBP could be another reason that explains
the improvement in glucose homeostasis after surgery [62].
In line with this, as the large gut microbiota population also
shifts in patients after GBP [30], it cannot be excluded that
motility disorders associated with long-standing obesity and
diabetes mellitus (e.g. due to autonomic diabetic neuropa-
thy) may affect small intestine gut microbiota composition,
yet data on this topic are lacking. Thus, further research
investigating the impact of intestinal anatomical alteration
on gut microbiota and consequent changes in food
ingestion and digestion is warranted.
Potential intervention in microbiota composition
The use of antibiotics to alter gut microbiota in genetically
obese mice reduced body weight, and improved fasting
glycaemia and glucose tolerance, suggesting that the gut
microbiota could be a novel target for treating metabolic
diseases [36, 63]. Concomitant reduction of LPS as well as
increased adiponectin levels enhanced the glucose-lowering
effects of antibiotics. Taking a reductionist approach, the
composition of intestinal microorganisms could be influ-
enced by changing exogenous dietary factors (e.g. butyrate
supplementation, oligofructose) or by transplantation of
human donor faeces [23, 44]. We are currently investigating
the effect of donor faeces transplantation (derived from lean
healthy participants) on glucose homeostasis and (intesti-
nal) inflammation in otherwise healthy participants with
metabolic syndrome (FATLOSE trial). This double-blind,
randomised, controlled trial will hopefully provide more
insight into microbiota and host physiology, as well as
into the effectiveness of gut microbiota manipulation in
humans.
Conclusions
Intestinal microbiota may play a pivotal role in converting
nutrients into energy. Variations in the composition of
microbiota are found in obese humans and mice. Increased
energy yield from diet in obese mice and humans could be
a contributing factor to obesity, although the pathophysio-
logical processes driving this bidirectional relationship have
not been fully elucidated. With the rapid developments in
(relatively cheap) high-throughput techniques (involving
phylogenetic microarrays based on small subunit rRNA
sequences and metagenomics approaches exploiting rapid
sequencing technologies), we might actually be able to
unravel the endocrinological potential of gastrointestinal
tract microbiota [64]. The last important clinical question
then remains: Is it possible to modify the gut microbiota to
reduce the impact of high-fat feeding on the occurrence of
metabolic disease in humans?
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